OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LOTS55

Lotus Eye Hospital and Institute Ltd

Healthcare Facilities & ServicesVerified

Lotus Eye Hospital and Institute Ltd maintains a strong liquidity position, with a current ratio of 2.25 and cash and equivalents of INR 25.82 million. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on debt financing. Despite this, the company reported an operating loss of INR 3.65 million in the latest period, which contrasts with its positive net income of INR 243,000. The company's profitability metrics are weak, with a return on equity of 0.04% and a return on assets of 0.04%. These figures are below the typical thresholds for healthcare facilities and services, suggesting that the company is not generating strong returns relative to its equity and asset base. Lotus Eye Hospital and Institute Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification information available in the provided data, but the company's operations are likely concentrated in India, given the INR-based financials and the ticker symbol LOTS.NS. The company's growth trajectory is uncertain, as the provided data does not include forward-looking revenue projections or historical growth rates. However, the operating loss in the latest period suggests that the company may be facing operational challenges that could impact its future growth. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt levels and strong cash position reduce the likelihood of near-term liquidity issues. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares to raise capital. There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial statements do not reference any major legal, regulatory, or operational developments in the latest reporting period.

30-day price · LOTS+4.72 (+4.6%)
Low$99.01High$129.79Close$106.56As of17 May, 00:00 UTC
Profile
CompanyLotus Eye Hospital and Institute Ltd
TickerLOTS.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Lotus Eye Hospital and Institute Ltd operates in the healthcare sector, providing eye care services and related treatments.

Classification. The company is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Lotus Eye Hospital and Institute Ltd maintains a strong liquidity position, with a current ratio of 2.25 and cash and equivalents of INR 25.82 million. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on debt financing. Despite this, the company reported an operating loss of INR 3.65 million in the latest period, which contrasts with its positive net income of INR 243,000. The company's profitability metrics are weak, with a return on equity of 0.04% and a return on assets of 0.04%. These figures are below the typical thresholds for healthcare facilities and services, suggesting that the company is not generating strong returns relative to its equity and asset base. Lotus Eye Hospital and Institute Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification information available in the provided data, but the company's operations are likely concentrated in India, given the INR-based financials and the ticker symbol LOTS.NS. The company's growth trajectory is uncertain, as the provided data does not include forward-looking revenue projections or historical growth rates. However, the operating loss in the latest period suggests that the company may be facing operational challenges that could impact its future growth. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt levels and strong cash position reduce the likelihood of near-term liquidity issues. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares to raise capital. There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial statements do not reference any major legal, regulatory, or operational developments in the latest reporting period.
Key takeaways
  • Lotus Eye Hospital and Institute Ltd has a strong liquidity position with a current ratio of 2.25 and INR 25.82 million in cash and equivalents.
  • The company's profitability is weak, with a return on equity of 0.04% and a return on assets of 0.04%.
  • The company's revenue is concentrated in a single business segment, and there is no geographic diversification information available.
  • The company reported an operating loss of INR 3.65 million in the latest period, which contrasts with its positive net income of INR 243,000.
  • The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$108.8M
Gross profit$55.8M
Operating income-$3.6M
Net income$243.0k
R&D
SG&A
D&A
SBC
Operating cash flow$56.8M
CapEx-$56.4M
Free cash flow
Total assets$666.3M
Total liabilities$72.2M
Total equity$594.1M
Cash & equivalents$25.8M
Long-term debt$11.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$323.7M$12.3M$15.7M$34.2M
FY-3$389.1M$33.6M$29.8M-$2.3M
FY-2$470.4M$46.1M$40.8M$29.2M
FY-1$482.1M$32.4M$29.1M-$406.0k
FY0$495.6M$8.7M$7.4M-$10.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$592.3M$527.0M$99.1M
FY-3$616.0M$546.1M$88.5M
FY-2$631.9M$575.8M$84.1M
FY-1$666.3M$594.1M$25.8M
FY0$695.7M$600.0M$41.5M
PeriodOCFCapExFCFSBC
FY-4$27.4M-$4.8M$34.2M
FY-3$43.9M-$46.8M-$2.3M
FY-2$43.9M-$31.0M$29.2M
FY-1$56.8M-$56.4M-$406.0k
FY0$27.0M-$48.3M-$10.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$108.8M-$3.6M$243.0k
FQ-6$128.9M$6.1M$6.2M
FQ-5$129.1M-$795.0k$1.0M
FQ-4$122.5M-$5.2M-$2.4M
FQ-3$115.1M$4.2M$2.5M
FQ-2$135.2M$6.6M$5.4M
FQ-1$130.4M-$736.0k$1.2M
FQ0$135.5M-$3.3M-$2.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$666.3M$594.1M$25.8M
FQ-6
FQ-5$700.7M$601.1M$45.4M
FQ-4
FQ-3$695.7M$600.0M$41.5M
FQ-2
FQ-1$715.1M$606.2M$32.5M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$56.8M-$56.4M
FQ-6
FQ-5$31.6M-$40.4M
FQ-4
FQ-3$27.0M-$48.3M
FQ-2
FQ-1$5.1M-$7.8M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$594.1M
Net cash$14.7M
Current ratio2.2
Debt/Equity0.0
ROA0.0%
ROE0.0%
Cash conversion233.9%
CapEx/Revenue-51.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricLOTSActivity
Op margin-3.3%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin0.2%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin51.2%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-51.8%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity2.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 02:08 UTC#d5e5a2bf
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 11:03 UTCJob: ce8c1fde